ESMO 2023 | Highlighting the benefits of KRAS testing in colorectal cancer

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the necessity of KRAS testing in colorectal cancer. The availability of sequencing assays and targeted therapies for specific KRAS mutations mean that patients with certain KRAS mutations will be eligible for certain treatments and will consequently benefit from testing. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.